Mechanisms of action of TNF-α and IL-6 in cancer pain

Cancer pain is a prevalent and often treatment-resistant complication of advanced cancer, highlighting the need for mechanism-based non-opioid targets. Inflammation within the tumor microenvironment is central to cancer pain, with TNF-α and IL-6 consistently implicated across preclinical models. However, these cytokines are typically studied as independent mediators. We propose that TNF-α and IL-6 may function as an integrated, putatively self-amplifying inflammator y axis. Acting through distinct receptor systems, TNFR1/TNFR2 and IL-6R/gp130, they converge on NF- κ B, MAPK, and PI3K-Akt signaling to drive transcriptional amplification, glial activation, and neuronal sensitization. Proposed reciprocal positive feedback and shared regulation of nociceptive effectors, including COX-2, TRPV1, TRPA1, and Nav1.8, may couple this axis to bone destruction, nerve injury, and tumor compression, thereby converting local inflammation into persistent pain. However, direct evidence for a self-amplifying circuit and synergistic analgesia in cancer pain remains limited. The integrated circuit and its proposed effects on cancer pain are inferred relationships that require experimental validation. Most mechanistic evidence derives from bone cancer pain and chemotherapy-induced neuropathy models, whereas several pathway-level observations rely on non-cancer models; accordingly, direct support across the broader spectrum of cancer pain remains limited. Although preclinical blockade of either cytokine attenuates cancer pain, direct causal evidence for synergy remains sparse, and systemic immunosuppression poses a major translational barrier. We argue that comparative single- versus dual-target blockade, combined with sex- and phenotype-stratified designs and local or time-limited delivery strategies, will be essential to determine whether the TNF-α/IL-6 axis is a precision non-opioid target in refractory cancer pain.